What is Chardan Capital’s Estimate for SLDB FY2025 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at Chardan Capital dropped their FY2025 earnings per share (EPS) estimates for Solid Biosciences in a research report issued to clients and investors on Tuesday, November 4th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of ($1.96) for the year, down from their prior estimate of ($1.82). Chardan Capital has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.06).

A number of other research analysts have also recently weighed in on SLDB. Cantor Fitzgerald set a $16.00 price target on shares of Solid Biosciences and gave the company an “overweight” rating in a research report on Monday, July 21st. JPMorgan Chase & Co. cut their target price on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a report on Wednesday, October 8th. Wall Street Zen downgraded Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Finally, Wedbush reduced their price objective on Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Solid Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $14.70.

Solid Biosciences Stock Performance

Shares of NASDAQ:SLDB opened at $4.06 on Friday. The stock has a 50-day simple moving average of $5.56 and a 200-day simple moving average of $5.05. The stock has a market capitalization of $316.31 million, a P/E ratio of -1.63 and a beta of 2.75. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $7.37.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. CWM LLC boosted its holdings in Solid Biosciences by 15,188.5% in the first quarter. CWM LLC now owns 7,950 shares of the company’s stock valued at $29,000 after purchasing an additional 7,898 shares during the last quarter. Legal & General Group Plc increased its holdings in Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after purchasing an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares in the last quarter. Ground Swell Capital LLC acquired a new position in shares of Solid Biosciences in the 1st quarter valued at approximately $42,000. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Solid Biosciences during the 2nd quarter valued at approximately $54,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.